邱源旺,男,教授,主任醫(yī)師,醫(yī)學(xué)博士,南京醫(yī)科大學(xué)、南通大學(xué)及江南大學(xué)碩士生導(dǎo)師,江南大學(xué)博士后聯(lián)合培養(yǎng)導(dǎo)師,江南大學(xué)附屬無(wú)錫五院副院長(zhǎng)。
現(xiàn)任中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)第五屆傳染病專業(yè)委員會(huì)委員、中華醫(yī)學(xué)會(huì)感染病學(xué)分會(huì)第十一屆委員會(huì)肝炎學(xué)組委員、中華醫(yī)學(xué)會(huì)感染病學(xué)分會(huì)肝衰竭與人工肝專家委員會(huì)委員、江蘇省醫(yī)學(xué)會(huì)感染病學(xué)分會(huì)常務(wù)委員、江蘇省醫(yī)院協(xié)會(huì)第六屆傳染病醫(yī)院分會(huì)常務(wù)委員、江蘇省中西醫(yī)結(jié)合學(xué)會(huì)肝病專業(yè)委員會(huì)委員、江蘇省第三屆艾滋病專業(yè)委員會(huì)委員、江蘇省醫(yī)師協(xié)會(huì)感染科醫(yī)師分會(huì)委員、無(wú)錫市醫(yī)學(xué)會(huì)感染病學(xué)專業(yè)委員會(huì)主任委員、無(wú)錫市感染性疾病質(zhì)控中心主任、無(wú)錫市醫(yī)院協(xié)會(huì)院感專業(yè)委員會(huì)副主任委員;《國(guó)際病毒學(xué)雜志》、《中西醫(yī)結(jié)合肝病雜志》、《現(xiàn)代醫(yī)藥雜志》編委,參與全國(guó)普通高等院校五年制臨床醫(yī)學(xué)專業(yè)規(guī)劃教材《傳染病學(xué)》編寫。
主要從事感染性疾病臨床診治及病毒性肝炎基礎(chǔ)和臨床研究工作。先后參與國(guó)家“十一五、十二五、十三五”艾滋病和病毒性肝炎等重大傳染病防治”科技重大專項(xiàng)子課題研究及國(guó)家重點(diǎn)研發(fā)計(jì)劃“新冠疫情臨床監(jiān)測(cè)預(yù)警體系構(gòu)建與應(yīng)用研究”項(xiàng)目,主持省市級(jí)課題8項(xiàng),研究成果已在J Infection(IF 38.637)、Emerg Microbes Infect、Front Immunol等國(guó)際和國(guó)內(nèi)期刊發(fā)表論文40余篇,其中SCI收錄論文15篇。獲中國(guó)醫(yī)院協(xié)會(huì)醫(yī)院科技創(chuàng)新二等獎(jiǎng)、江蘇省醫(yī)學(xué)新技術(shù)引進(jìn)二等獎(jiǎng)及無(wú)錫市科技進(jìn)步三等獎(jiǎng)各1項(xiàng)。榮獲第五屆江蘇省“百名醫(yī)德之星”、無(wú)錫市“十大醫(yī)德標(biāo)兵”。近3年指導(dǎo)碩士研究生5名、博士后1名。
代表性論文:
[1] Immunogenicity of a third dose of inactivated COVID-19 vaccine in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: A cross-sectional study.JOURNAL OF INFECTION.2022,85 (4):e109-e111.(通訊作者)
[2] COVID-19: imbalanced cell-mediated immune response drives to immunopathology.Emerging microbes & infections.2022,11 (1):2393-2404.(通訊作者)
[3] CCL28 mucosal expression in SARS-CoV-2-infected patients with diarrhea in relation to disease severity.JOURNAL OF INFECTION.2021,82 (1):e19-e21(通訊作者)
[4] Characterizing COVID-19 severity, epidemiology and SARS-CoV-2 genotypes in a regional business hub of China.JOURNAL OF INFECTION.2021,82 (2):282-327.(通訊作者)
[5] Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19.Frontiers in immunology.2020,11:2063. (通訊作者)
[6] Acute-on-Chronic Liver Failure From Chronic-Hepatitis-B, Who Is the Behind Scenes.Frontiers in microbiology.2020,11:583423. (通訊作者)
[7] Develop and validate a novel online AIHI-nomogram to predict severe liver inflammation in patients with autoimmune hepatitis.Annals of Hepatology.2023,28 (6):101134. (通訊作者)
[8] IL-21 Is Associated With Virological Relapse of HBeAg Positive Chronic Hepatitis B After Discontinuance of Entecavir.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.2021,32 (2):178-186.(通訊作者)
[9] The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus.INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES.2013,17 (8):e606-9.
[10] Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES.2016,43:43-48.